You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR inhibitor

Showing 1 - 25 of 9,414
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Changsha (BEBT-109)

Completed
  • NSCLC
  • Changsha, Hunan, China
    Hunan Cancer hospital
Aug 20, 2023

NSCLC Trial in Omaha (PLB1004)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Omaha, Nebraska
    Nebraska Cancer Specialists
Sep 19, 2023

Acneiform Eruptions Trial in Shanghai (Cream containing JAK Inhibitor)

Recruiting
  • Acneiform Eruptions
  • Cream containing JAK Inhibitor
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Jun 20, 2022

Colorectal Cancer Metastatic, C-met Overexpression Trial in Rozzano (Tivantinib (ARQ197))

Completed
  • Colorectal Cancer Metastatic
  • C-met Overexpression
  • Tivantinib (ARQ197)
  • Rozzano, Milano, Italy
    Istituto Clinico Humanitas
Sep 8, 2022

EGFR Inhibitor-Induced Skin Rash Trial in Taipei, Taoyuan (AC-701 Topical Gel 0.3%, Placebo Gel)

Completed
  • EGFR Inhibitor-Induced Skin Rash
  • AC-701 Topical Gel 0.3%
  • Placebo Gel
  • Taipei, Taiwan
  • +1 more
Apr 25, 2022

NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
  • +3 more
Aug 1, 2022

EGFR Inhibitor Induced Acneiform Lesions Trial in Israel, United States (LUT014)

Completed
  • EGFR Inhibitor Induced Acneiform Lesions
  • Los Angeles, California
  • +5 more
Apr 5, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Non Small Cell Lung Cancer Trial in Beijing (DZD9008)

Recruiting
  • Non Small Cell Lung Cancer
  • Beijing, Beijing, China
    Department of Respiratory and Critical Care Medicine, Peking Uni
Sep 24, 2022

NSCLC Trial in Boston (Osimertinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Boston, Massachusetts
  • +1 more
Sep 28, 2022

Malignant Tumor Trial in United States (Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration)

Recruiting
  • Malignant Neoplasm
  • Danville, Illinois
  • +5 more
Apr 13, 2022

LMV-12 Combined With Osimertinib in NSCLC

Not yet recruiting
  • Non Small Cell Lung Cancer
  • LMV-12(HE003) and Osimertinib
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 25, 2023

Paronychia, Epidermal Growth Factor Receptor Inhibitor Trial in Taipei (Timolol maleate 0.5% ophthalmic solution, Cryotherapy

Recruiting
  • Paronychia
  • Epidermal Growth Factor Receptor Inhibitor
  • Timolol maleate 0.5% ophthalmic solution
  • Cryotherapy with liquid nitrogen
  • Taipei, Taiwan
    Taipei Municipal Wan-Fang Hospital
Jun 7, 2022

Brain Metastases, NSCLC Trial in Shanghai (EGFR-TK Inhibitor, Stereotactic radiotherapy)

Recruiting
  • Brain Metastases
  • Non-small Cell Lung Cancer
  • EGFR-TK Inhibitor
  • Stereotactic radiotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 27, 2023

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma Trial in France, United Kingdom, United States (NUC-3373 +

Recruiting
  • Colorectal Cancer
  • +4 more
  • NUC-3373 + leucovorin
  • +8 more
  • Boston, Massachusetts
  • +9 more
Jan 23, 2023

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

NSCLC Trial (Chemotherapy, Alflutinib plus chemo)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jan 25, 2022

Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

Completed
Has Results
  • Lymphoma, Large-Cell, Anaplastic
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Jul 26, 2021

NSCLC With EGFR Mutation, Brain Metastases Trial in China (Keynatinib)

Recruiting
  • Non-Small Cell Lung Cancer With EGFR Mutation
  • Brain Metastases
  • Beijing, Beijing, China
  • +4 more
Apr 17, 2022

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

Recruiting
  • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
  • Topical Timolol
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 14, 2023